Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
Loading
Revenue ScalingExpanding
Percentile Rank100
3Y CAGR+53.0%
5Y CAGR+49.8%
Year-over-Year Change
Total revenue from sales of goods and services
3Y CAGR
+53.0%/yr
vs +92.9%/yr prior
5Y CAGR
+49.8%/yr
Recent acceleration
Acceleration
-39.9pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
7.5x
Strong expansion
Streak
7 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $3.71B | +65.2% |
| 2024 | $2.25B | +23.0% |
| 2023 | $1.83B | +76.2% |
| 2022 | $1.04B | +22.9% |
| 2021 | $844.29M | +71.3% |
| 2020 | $492.85M | +124.3% |
| 2019 | $219.75M | +193.4% |
| 2018 | $74.91M | -16.7% |
| 2017 | $89.91M | +90.7% |
| 2016 | $47.16M | - |